Healthcare Sales & Marketing Network News: tumor microenvironment

Searching News Database: tumor microenvironment

HSMN NewsFeed - 9 Sep 2022
Nouscom Strengthens Leadership Team with the Appointments of Sven Gogov, MD, as Chief Medical Officer and Maria Arce-Tomas, PhD, as VP, Head of Regulatory Affairs
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 9 Aug 2022
ImmPACT Bio Names Vikram Lamba as Chief Financial Officer and Head of Business Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Jul 2022
Novasenta Completes $40 million Series A to Advance Novel Cancer Therapeutics
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Jul 2022
Kernal Biologics Announces $25M Series A Financing to Advance its mRNA 2.0 Technology for Oncology
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 19 May 2022
Inceptor Bio Announces $37 Million Series A Financing to Develop Cell Therapies for Difficult-to-Treat Cancers
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 16 May 2022
Promontory Therapeutics Appoints Johan Baeck, MD, as Executive Vice President and Chief Medical Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Apr 2022
OncoSec Appoints Dr. Robert Arch as President and Chief Executive Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Apr 2022
Jazz Pharmaceuticals and Werewolf Therapeutics Announce Exclusive Global License and Collaboration Agreement to Develop WTX-613, a Differentiated, Conditionally-Activated IFNα INDUKINE(TM) Molecule
Biopharmaceuticals Licensing

HSMN NewsFeed - 7 Apr 2022
LTZ Therapeutics Secures $17 Million Pre-Series A Financing for Immunotherapy Development to Treat Cancer & Other Complex Diseases
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 2 Mar 2022
Rondo Therapeutics Closes $67 Million Series A Financing to Advance Next-Generation Immuno-Oncology Platform for Solid Tumors
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 17 Dec 2021
OncoSec Announces Changes to its Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 7 Dec 2021
Corbus Pharmaceuticals Appoints Rachael Brake, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 1 Dec 2021
Curie Therapeutics Raises $75 Million Financing to Further its Mission of Transforming Cancer Care with Precision Radiopharmaceuticals
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 11 Nov 2021
Actym Therapeutics Appoints Chan Whiting as Chief Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Nov 2021
Biond Biologics Announces Closing of $15 Million Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 7 Oct 2021
AffyImmune Therapeutics Announces $30M Series A+ Financing from ORI Capital
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 6 Aug 2021
BioInvent Announces Second Clinical Trial Collaboration and Supply Agreement to Evaluate BI-1808 in Combination with KEYTRUDA(R) (pembrolizumab) in Patients with Advanced Solid Tumors
Biopharmaceuticals Oncology

HSMN NewsFeed - 17 Jun 2021
KaliVir Immunotherapeutics Appoints Drs. Terry Hermiston and Jon Wigginton to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 1 Jun 2021
Kineta Closes $10 Million Financing Round to Advance Anti-VISTA Immuno-oncology Program
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 14 Apr 2021
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse(TM)" for the Treatment of Solid Tumors
Devices Oncology Regulatory

HSMN NewsFeed - 16 Mar 2021
Merck KGaA, Darmstadt, Germany, Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 18 Feb 2021
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Feb 2021
OncoSec Strengthens Management Team With Two New Appointments
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Jan 2021
Werewolf Therapeutics Completes $72 Million Series B Financing to Advance a Novel Class of Cancer Biotherapeutics to the Clinic
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 6 Jan 2021
Myeloid Therapeutics Launches with Over $50 Million in Financing and Two Clinical Trials
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 7 Dec 2020
KaliVir Immunotherapeutics and Astellas Enter Worldwide Exclusive Licensing Agreement for Development and Commercialization of VET2-L2 Novel Oncolytic Virus
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 2 Dec 2020
HiberCell Bolsters Leadership Team with Appointment of Joseph Talamo as Chief Financial Officer and Promotion of Ari Nowacek, M.D., Ph.D., to Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Oct 2020
OncoSec Announces Appointment of Sandra Aung, Ph.D. as Senior Vice President, Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Sep 2020
Leap Therapeutics Announces FDA Fast Track Designation Granted to DKN-01 for the Treatment of Gastric and Gastroesophageal Junction Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 9 Sep 2020
Phosplatin Therapeutics Announces Two Leadership Appointments
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Aug 2020
Phosplatin Therapeutics Completes $18.4 Million Private Financing Round
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 10 Aug 2020
Werewolf Therapeutics Appoints Business Leader, Ellen Lubman, as Chief Business Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 27 Jul 2020
CARISMA Therapeutics Announces FDA Clearance of IND Application for First-Ever Engineered Macrophage Immunotherapy
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 Jul 2020
HiberCell Announces Acquisition of Biothera Pharmaceuticals' Imprime PGG Program
Biopharmaceuticals Oncology Acquisitions

HSMN NewsFeed - 27 Apr 2020
Actym Therapeutics Raises $34 Million Series A
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 25 Feb 2020
Oncologie, Inc. Announces Collaboration with Moffitt Cancer Center to Advance the Development of Precision Medicine for the Treatment of Gastric and Gastrointestinal Cancers
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2020
Presage Receives FDA Clearance of First IND Application for Trial to Evaluate Investigational Oncology Agents with CIVO(TM) Technology
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 3 Jan 2020
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 20 Nov 2019
Werewolf Therapeutics Launches with $56M Series A Financing to Develop Transformative Immuno-Stimulatory Cancer Medicines
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 27 Aug 2019
PIONYR Immunotherapeutics Announces Key Leadership Team Addition and Clinical Candidates Targeting Tumor-Associated Macrophages
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 22 Aug 2019
Torque Expands Leadership Team with Appointment of Sok Cheng Soh as CFO and Ana Radeljevic as VP, Head of Business Operations
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 12 Aug 2019
Oncologie, Inc. Announces Clinical Trial Collaboration With Merck to Evaluate Bavituximab in Combination With KEYTRUDA(R) (Pembrolizumab) in Advanced Gastric or Gastroesophageal Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Jul 2019
Halozyme Announces Janssen Submits Extension Application To European Medicines Agency For Subcutaneous Formulation Of DARZALEX(R) Utilizing ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery Regulatory

HSMN NewsFeed - 27 Jun 2019
OncoSec Receives Exclusive Licensing Rights from Dana-Farber Cancer Institute to CAR T-Cell Therapies for the Treatment of Solid Tumor Cancers
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 18 Jun 2019
FDA Grants Fast Track Designation for Torque's First Deep-Primed T Cell Cancer Immunotherapy Program, TRQ-1501
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 10 Jun 2019
Oncologie Closes an $80M Series B Financing for Clinical-Stage Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 22 May 2019
Halozyme Announces argenx Has Selected Second Target Under ENHANZE(R) Technology Collaboration And License Agreement
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 6 May 2019
Halozyme Names Dr. Alison A. Armour As Senior Vice President of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 24 Apr 2019
OncoSec Appoints Industry Veteran Margaret R. Dalesandro, Ph.D., to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 10 Apr 2019
OncoSec Announces New Technology to Treat Deep Visceral Lesions with IL-12
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 1 Apr 2019
OncoSec Announces Advanced Therapy Medicinal Product Classification from the EMA for TAVO(TM) in Refractory Metastatic Melanoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 4 Feb 2019
argenx and Halozyme Enter Global Collaboration and License Agreement for ENHANZE(R) Technology
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 10 Jan 2019
GigaGen Announces Appointment of Erica Stone, Ph.D., as Director, Immuno-Oncology
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 21 Dec 2018
OncoSec Announces Appointment Of Joon Kim, J.D., To Board Of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 8 Nov 2018
OncoSec Appoints Robert Ward to its Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 2 Nov 2018
Torque Announces Appointment of Immunotherapy Pioneer F. Stephen Hodi, MD, to Scientific Advisory Board and Alex Bruni as COO/ CFO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 29 Oct 2018
OncoSec Appoints Kellie Malloy Foerter as Chief Clinical Development Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Sep 2018
Halozyme Announces Approval Of Subcutaneous Formulation Of Trastuzumab (Herceptin(R)) In Canada
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 10 Sep 2018
Halozyme Appoints Bernadette Connaughton To Board Of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Sep 2018
Halozyme Names Benjamin Hickey As Chief Commercial Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Sep 2018
OncoSec Announces $15 Million At Market Investment from Alpha Holdings, Inc.
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 28 Aug 2018
OncoSec Appoints Alain Algazi, MD, as Clinical Strategic Advisor
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 23 Aug 2018
Tocagen's Toca 5 Pivotal Phase 3 Clinical Trial in Patients with Recurrent Brain Cancer Continues Without Modification at Planned First Interim Analysis
Biopharmaceuticals Neurology Oncology

HSMN NewsFeed - 30 Jul 2018
OncoSec Appoints Robert W. Ashworth, Ph.D. as Vice President, Regulatory
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 26 Jul 2018
Phase 3 Study Of Subcutaneous Pertuzumab And Trastuzumab Initiated Using Halozyme's ENHANZE(R) Technology
Biopharmaceuticals Oncology Drug Delivery

HSMN NewsFeed - 25 Jul 2018
Torque Appoints James Mullen as Chairman of Board of Directors, Maykin Ho, PhD, as Strategic Advisor to the Board of Directors, and Mario Sznol, MD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Jul 2018
FDA Accepts Biologics License Application For Subcutaneous Formulation Of Herceptin
Biopharmaceuticals Drug Delivery Oncology FDA

HSMN NewsFeed - 28 Jun 2018
Thermo Fisher Scientific Expands Oncomine Immuno-Oncology Assay Portfolio
Diagnostics Product Launch

HSMN NewsFeed - 14 Jun 2018
Apexigen and Yale Cancer Center Announce Clinical Collaboration to Evaluate APX005M, Cabiralizumab, and Opdivo (Nivolumab) in Patients whose Disease has Progressed on Anti-PD-1/PD-L1 Therapy
Biopharmaceuticals Oncology

HSMN NewsFeed - 2 May 2018
Refuge Biotechnologies Completes $25 Million Series B Financing, Appoints CSO to Advance the Development of Intelligent Cell Therapies in Oncology
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 19 Apr 2018
Tocagen and ApolloBio Enter License Agreement to Develop and Commercialize Toca 511 & Toca FC in the Greater China Region
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 14 Mar 2018
Torque Appoints John Hohneker, MD, to Board of Directors and Marcela Maus, MD, PhD, to Scientific Advisory Board
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 14 Sep 2017
Halozyme Licenses New Enhanze Target For $30 Million Upfront Payment, Future Milestones And Royalties
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 23 Aug 2017
Macrophage Pharma Limited Extends Series A Round to Include New Investor Merck Ventures
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 5 Jun 2017
New Data Presented at ASCO 2017 Finds IMBRUVICA(R) (ibrutinib) May Offer a More Targeted Approach to Chronic Lymphocytic Leukemia (CLL) Treatment than Chemotherapy Agent Chlorambucil in Treatment-Na�ve Patients
Biopharmaceuticals Oncology

HSMN NewsFeed - 19 Apr 2017
Advaxis Appoints Anthony Lombardo as Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 17 Apr 2017
OncoMed�s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Mar 2017
CytomX Therapeutics Appoints Marion McCourt to Board of Directors
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 20 Mar 2017
Bristol-Myers Squibb and CytomX Therapeutics Extend Worldwide Collaboration to Discover Probody(TM) Therapeutics for the Treatment of Cancer and Other Diseases
Biopharmaceuticals Oncology

HSMN NewsFeed - 22 Feb 2017
Mitra Appoints Anton Ehrhardt as Vice President of Medical Affairs
Diagnostics Oncology Personnel

HSMN NewsFeed - 20 Jan 2017
Verastem Announces Executive Leadership Appointments and Changes
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 4 Jan 2017
Corvus Pharmaceuticals Names Ian T. Clark, Former Genentech Chief Executive Officer, to Board of Directors
Biopharmaceuticals Personnel

HSMN NewsFeed - 19 Dec 2016
Northern Biologics, Mosaic Biomedicals Execute Transformative Deal
Biopharmaceuticals Oncology Mergers & Acquisitions

HSMN NewsFeed - 3 Nov 2016
FDA Accepts Genentech's Biologics License Application For Subcutaneous Formulation Of Rituximab
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 2 Nov 2016
Turnstone Biologics Raises $41.4 Million Series B Financing
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 2 Nov 2016
Verastem Licenses Duvelisib from Infinity Pharmaceuticals
Biopharmaceuticals Oncology Licensing

HSMN NewsFeed - 28 Oct 2016
Astellas to Acquire Ganymed Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 1 Sep 2016
Immune-Onc Therapeutics, Inc. Announces $7 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 17 Aug 2016
Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 12 Jul 2016
Advaxis Appoints Ranya Dajani as Vice President, Corporate Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 5 Jul 2016
Bristol-Myers Squibb Acquires Cormorant Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions

HSMN NewsFeed - 29 Jun 2016
Corvus Pharmaceuticals Names Jason V. Coloma to Newly Created Post of Chief Business Officer
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 21 Jan 2016
Halozyme Announces First Clinical Dosing Of Adalimumab (Humira) Using ENHANZE(TM) Technology
Biopharmaceuticals Drug Delivery Licensing

HSMN NewsFeed - 21 Dec 2015
Halozyme Enters Into Global Collaboration And Licensing Agreement With Lilly
Biopharmaceuticals Licensing

HSMN NewsFeed - 16 Dec 2015
BIND Therapeutics Appoints Jonathan Yingling, Ph.D., as Chief Scientific Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 4 Nov 2015
Flagship Ventures Launches Evelo Therapeutics To Develop Microbiome Therapies for Cancer
Biopharmaceuticals Oncology Venture Capital Personnel

HSMN NewsFeed - 24 Sep 2015
Replimune Ltd Raises $30 Million Series A Financing
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Sep 2015
Deciphera Pharmaceuticals Announces $75 Million Series B Financing to Advance Novel Oncology Pipeline
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 18 Sep 2015
Infinity Expands Pipeline with Addition of IPI-549, an Immuno-Oncology Development Candidate for the Treatment of Solid Tumors
Biopharmaceuticals Acquisitions

HSMN NewsFeed - 15 Sep 2015
Molecular Response Appoints the Former Head of Translational Medicine Oncology at MedImmune/AstraZeneca, Brett Hall, Ph.D., as Chief Executive Officer
Diagnostics Personnel

HSMN NewsFeed - 27 Aug 2015
Immuno-Oncology Veteran Rachel Humphrey, M.D., Joins CytomX as Chief Medical Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 3 Aug 2015
CytomX Announces Management Team Promotions
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 3 Feb 2015
U.S. FDA Grants Priority Review for YONDELIS(R) (trabectedin) for the Treatment of Patients with Advanced Soft Tissue Sarcoma
Biopharmaceuticals Oncology

HSMN NewsFeed - 27 Jan 2015
Euclises Announces Appointment of Bobby Sandage as New CEO
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 6 Jan 2015
CytomX Raises $20 Million in Series C Round Led by Pfizer Venture Investments
Biopharmaceuticals Oncology Venture Capital

HSMN NewsFeed - 21 Apr 2014
OncoSec Medical Appoints Jean S. Campbell, Ph.D. as Executive Director of Research and Development
Biopharmaceuticals Oncology Personnel

HSMN NewsFeed - 7 Apr 2014
Deciphera Pharmaceuticals Appoints Michael D. Taylor, Ph.D., as President and Chief Executive Officer
Biopharmaceuticals Personnel

HSMN NewsFeed - 25 Mar 2014
Exelixis Receives Approval for COMETRIQ(R) (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 20 Feb 2014
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Colorectal Cancer after Resection of Liver Metastases
Biopharmaceuticals Oncology

HSMN NewsFeed - 9 Jan 2014
CytomX Therapeutics and ImmunoGen, Inc. Announce Strategic Collaboration to Develop Probody-Drug Conjugates Against Cancer Targets
Biopharmaceuticals Oncology

HSMN NewsFeed - 4 Oct 2013
MetaStat's MetaSite Breast(TM) Diagnostic Assay Predicts Metastasis in Breast Cancer Study
Diagnostics Oncology

HSMN NewsFeed - 13 Sep 2013
Aethlon Medical Announces Dr. Douglas Taylor as Chief Scientific Officer of Exosome Sciences, Inc.
Diagnostics Personnel

HSMN NewsFeed - 30 Aug 2013
Bayer's Stivarga(R) (regorafenib) Tablets Approved in Europe
Biopharmaceuticals Oncology Regulatory

HSMN NewsFeed - 15 May 2013
Bayer Initiates Phase III Trial of Stivarga(R) (regorafenib) Tablets in Patients with Advanced Liver Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 29 Oct 2012
Bayer's Stivarga(R) (regorafenib) Tablets New Drug Application Granted Priority Review by U.S. FDA for the Treatment of Patients with Gastrointestinal Stromal Tumors
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 27 Sep 2012
Bayer's Stivarga(R) (regorafenib) Tablets Approved by U.S. FDA for Treatment of Metastatic Colorectal Cancer
Biopharmaceuticals Oncology FDA

HSMN NewsFeed - 7 May 2012
Ruga Corporation Expands Management Team to Advance Its Adaptive Response Therapeutics for Cancer Patients
Biopharmaceuticals Personalized Medicine Personnel

HSMN NewsFeed - 11 Oct 2010
Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
Biopharmaceuticals Oncology

HSMN NewsFeed - 30 Jun 2010
Calistoga Pharmaceuticals Raises $40 Million in Series C Financing
Biopharmaceuticals Venture Capital

HSMN NewsFeed - 8 Jun 2010
New ABRAXANE(R) Data Demonstrates Potential in Patients with Advanced and Malignant Melanoma, Among the Toughest Cancers to Treat
Biopharmaceuticals Oncology

Return to NewsFeed

Additional items found! 6

Members: click here for search results from The HSMN Archive (password required)

Members Archive contains 6 additional stories matching:
tumor microenvironment
(Password required)

FindReps - available on the Apple App Store for iPhone and iPad.